Efficacy of frankincense-based herbal product in urinary incontinence: A randomized, double-blind, placebo- and active-controlled clinical trial

Phytother Res. 2023 May;37(5):1754-1770. doi: 10.1002/ptr.7691. Epub 2022 Nov 28.

Abstract

Urinary incontinence is a silent epidemic that has a serious impact on a person's quality of life (QOL). This study aimed to evaluate the efficacy of frankincense-based herbal product (FHP) in urinary incontinence compared with placebo and solifenacin. In this randomized, double-blind clinical trial, 120 postmenopausal women with mixed urinary incontinence were randomized to one of the three groups of FHP, placebo, and standard treatment (solifenacin). Frequency, amount of leakage, and score of urinary incontinence as well as the QOL were measured at the end of the second and fourth weeks and 2 weeks after the interruption of the treatment. The ICIQ-UI SF and I-QOL questionnaires were used for the measurements. Mean frequency of urinary incontinence and amount of leakage significantly decreased in the FHP and solifenacin groups in the fourth week compared to the placebo group. In addition, 2 weeks after treatment completion, the effects of the FHP were significant compared to the solifenacin group. Due to the effect of FHP on improving the QOL and also the prolonged effect of this drug, the use of FHP in urinary incontinence, as a complementary treatment could be suggested.

Keywords: Boswellia sacra; frankincense; piperine; quality of life; urinary incontinence.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Boswellia*
  • Double-Blind Method
  • Female
  • Frankincense* / therapeutic use
  • Humans
  • Quality of Life
  • Solifenacin Succinate / therapeutic use
  • Treatment Outcome
  • Urinary Incontinence* / drug therapy

Substances

  • Solifenacin Succinate
  • Frankincense